Cysteamine

SkinnyFit, SuperFeast USA, Elderwise Organics, and Senté Labs Win HealthXWire Awards for Most Innovative New Healthcare Products of 2023

Retrieved on: 
Thursday, June 15, 2023
Weight loss, Cysteamine, USD, Science, Silybum, Cosmeceutical, Bloating, Longevity, Health, Qi, Traditional Chinese medicine, HSA, Spice, Skin, Speciality chemicals, Hunting

NEW YORK, June 15, 2023 /PRNewswire/ -- Four companies offering exceptional and outstanding health support supplements and cosmeceuticals have won special recognition for offering the Most Innovative New Healthcare Products for 2023 from HealthXWire, a digital publication focusing on health, wellness, and longevity. [See full press release.]

Key Points: 
  • HealthXWire has recognized four providers of health support supplements and cosmeceuticals with its award for Most Innovative New Healthcare Product of 2023.
  • Each of these companies is an innovative entrepreneurial enterprise with a truly exceptional product that is the best in its class.
  • In an increasingly competitive market, these outstanding companies provide the best that science and tradition have to offer for the discerning customer seeking unique and effective products for self-care.
  • NEW YORK, June 15, 2023 /PRNewswire/ -- Four companies offering exceptional and outstanding health support supplements and cosmeceuticals have won special recognition for offering the Most Innovative New Healthcare Products for 2023 from HealthXWire , a digital publication focusing on health, wellness, and longevity.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Tissue, Central nervous system, Gene, Comorbidity, Gastrointestinal disease, Health care, Food, Aes, Food and Drug Administration, Skin, Liver, Brain, SOC, Stem cell, Beery, Cystinosis, Metabolism, AVRO, Cystine, Clinical trial, Patient, Standard of care, Blood, Cell, Cysteamine, HSC, MRCP, FDA, FFPM, Safety, Neuropathology, Society, DSM-IV codes, MHRA, Disease, Pharmaceutical industry, Vaccine, Medical imaging

These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.

Key Points: 
  • These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.
  • “We are excited about moving this investigational gene therapy closer to patients.”
    In addition to the data presented, the Company also announced positive and productive meetings with the U.K.
  • Preliminary data from this trial suggest that this HSC gene therapy is well tolerated, with no AEs related to the drug product to date.
  • An oral presentation by Dr. Cherqui on these data, “Phase 1/2 Clinical Trial of Autologous Hematopoietic Stem and Progenitor Cell Gene Therapy for Cystinosis,” will occur today at 3:45 PM PT in the session Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease II of the ASGCT Annual Meeting.

Worldwide Rare Kidney Diseases Industry Report to 2035 - Key Market Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Pharmaceutical, Health, Other Health, Molecule, Lupus nephritis, Fabry disease, Dialysis, Disorder, Kidney, European Medicines Agency, Cystinosis, Renal tubular acidosis, Diagnosis, RKD, EMA, Patient, Prevalence, Biopsy, Food and Drug Administration, Research, Hospital, Atypical hemolytic uremic syndrome, LN, Diabetes, Incidence, COVID-19, Survival, Ahus, Administration, Mortality, USFDA, USD, Pharmaceutical industry, Cysteamine, IgA nephropathy

The "Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney diseases market, over the next decade.
  • The term rare kidney diseases (RKD) represents around 150 different indications.
  • It is worth highlighting that the prevalence rate of rare kidney diseases is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe.

Senté Launches Cysteamine HSA Pigment & Tone Corrector, targeting inflammation and pigmentation

Retrieved on: 
Monday, August 15, 2022
Dermatology, Multimedia, Pigment, Cysteamine, Risk, Sent, FAAD, HSA, Skin care, Physician, Patient, Skin, Hyperpigmentation, Cosmetics, MD

CARLSBAD, Cal., Aug. 15, 2022 /PRNewswire/ -- Sent, an innovative specialty dermatology company, announces the launch of Cysteamine HSA Pigment & Tone Corrector to safely and effectively target pigmentation in all skin tones.

Key Points: 
  • CARLSBAD, Cal., Aug. 15, 2022 /PRNewswire/ -- Sent, an innovative specialty dermatology company, announces the launch of Cysteamine HSA Pigment & Tone Corrector to safely and effectively target pigmentation in all skin tones.
  • In a randomized, double-blind clinical trial of 35 subjects with moderate to severe hyperpigmentation, Sent Cysteamine HSA Pigment & Tone Corrector demonstrated a 71% overall reduction in dark spots1, while94% of subjects showed improvement in hyperpigmentation at 16 weeks.
  • Cysteamine HSA Pigment & Tone Corrector goes beyond treating the appearance of dark spots to actually helping patients reclaim their natural skin tone.
  • "Sent Cysteamine HSA Pigment & Tone Corrector is showing great success for patients with hyperpigmentation.

AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran® (cysteamine ophthalmic solution) 0.44%

Retrieved on: 
Tuesday, March 22, 2022
Pancreas, Risk, Induced coma, Organization, Pharmacy, Headache, Degenerative disease, Partnership, Research, Eyelid, Program, Leadiant Biosciences, Patient, Cystinosis, Food, Tissue, Pharmacist, Contact lens, Senior, Light, Quality of life, Regulation of tobacco by the U.S. Food and Drug Administration, Muscle, Cystine, Mark (given name), FDA, Hospital, Pharmaceutical industry, Health insurance, Walgreens, Cysteamine

ORLANDO, Fla., March 22, 2022 /PRNewswire/ -- Leadiant Biosciences, Inc. has partnered with AllianceRx Walgreens Prime – one of the largest specialty and home delivery pharmacies in the U.S. – to be the exclusive specialty pharmacy and clinical support provider for its rare disease drug Cystaran.

Key Points: 
  • "We have had a nearly decade-long partnership which is why Leadiant Biosciences has entrusted us as the exclusive specialty pharmacy to support the relaunch of Cystaran.
  • As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients, according to James.
  • Leadiant Biosciences recently relaunched the brand with revised packaging through the exclusive agreement with AllianceRx Walgreens Prime.
  • "Leadiant Biosciences is pleased to continue its long-standing partnership with AllianceRx Walgreens Prime," says Mike Minarich, Chief Executive Officer, Leadiant Biosciences.

Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis

Retrieved on: 
Wednesday, March 9, 2022
Lists of diseases, Insilico Medicine, Library, Phenotype, Lysosome, Kidney, UZH, Gonad, University, Hypogonadism, Kidney disease, Mechanism, Risk, Pancreas, CTNS, Research, Public health, Therapy, FDA, AI, Artificial intelligence, Cancer, Cystinosis, Cystine, Tissue, Quality of life, Fanconi syndrome, Diabetes, CNS, CKD, Glycogen storage disease, Chemistry, NEW, MD, Metabolism, Brain, Cysteamine, Patient, Epithelium, Muscle, Central nervous system, Omics, Solution, Zebrafish, Biology, Knowledge, Chronic kidney disease, Fibrosis, Immunity, Disease, Myopathy, Intelligence, Hypothyroidism, CEO, Liver, Pharmaceutical industry, Medical device, In silico

NEW YORK and ZURICH, March 9, 2022 /PRNewswire/ -- The MIKADO group, a translational team at the UZH focused on generating evidence-driven insights to understand and treat rare inherited kidney diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI)-driven drug discovery company, today announced a research and development collaboration designed to accelerate the discovery of transformative novel therapeutics for cystinosis. The duration of the initial research collaboration will be one year.

Key Points: 
  • Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain.
  • - The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis.
  • The duration of the initial research collaboration will be one year.
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis

Retrieved on: 
Wednesday, March 9, 2022
Insilico Medicine, Library, Phenotype, Lysosome, Kidney, UZH, Hypogonadism, Kidney disease, Pancreas, Research, CTNS, Public health, Therapy, FDA, AI, Artificial intelligence, Cancer, Cystinosis, Cystine, Tissue, Diabetes, Quality of life, Fanconi syndrome, CNS, CKD, Glycogen storage disease, Chemistry, MD, Multimedia, Metabolism, Brain, Cysteamine, Patient, Epithelium, Muscle, Central nervous system, Omics, Solution, Zebrafish, Biology, Knowledge, Chronic kidney disease, Fibrosis, Immunity, Disease, Myopathy, Intelligence, Hypothyroidism, Lists of diseases, CEO, Liver, Pharmaceutical industry, Medical device, In silico

"I am thrilled by the collaboration between MIKADO and Insilico.

Key Points: 
  • "I am thrilled by the collaboration between MIKADO and Insilico.
  • We are pleased to partner with MIKADO at the UZH combining the best of PandaOmics target discovery AI and human intelligence for the potential benefit of cystinosis patients worldwide," said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

Cyspera® Launches New Three-Step System with Novel Pigment Corrector to Treat Hyperpigmentation

Retrieved on: 
Thursday, February 17, 2022
Skin discoloration, Hyperpigmentation, Lactobionic acid, Patient, Tissue, Epidermis, Science, Color, AHA, Complex, B3, Smell, MD, Chemistry (relationship), Self-assessment, Alabama School of Fine Arts, Cysteamine, Pigment, Multimedia, University, Skin, General manager, Cosmetics, Personal protective equipment, Fine chemical, Online shopping, Medicine, Dermatology

Sold at hundreds of dermatologist offices nationwide without a prescription, this novel pigment corrector is the next breakthrough in the fight against stubborn hyperpigmentation.

Key Points: 
  • Sold at hundreds of dermatologist offices nationwide without a prescription, this novel pigment corrector is the next breakthrough in the fight against stubborn hyperpigmentation.
  • "Dermatology professionals in the US are embracing Cyspera as a proven first line non-hydroquinone option that can be used routinely."
  • "It is also one of the trickiest to treat which is why I recommend the Cyspera Intensive System to my patients who after four weeks, start to see visible results."
  • Cyspera is a novel intensive pigment corrector formulated with cysteamine to address the appearance of stubborn discoloration.

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Retrieved on: 
Wednesday, February 9, 2022
Health, FDA, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Industry, Phrase, Growth, AES, U.S. Securities and Exchange Commission, Chronic kidney disease, Skin, Stem cell, Glycogen storage disease type II, Lists of diseases, Investor, Twitter, Lysosome, Clinical trial, Safety, HIV disease progression rates, Risk, FDA, Technology, Patient, Cystine, Security (finance), Adult, Brain, Cysteamine, Cystinosis, CEO, AVRO, Life, End organ damage, VCN, United Kingdom, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Kidney transplantation, Disease, Webcast, Data collection, Interim, Food, LinkedIn, Hunter syndrome, COVID-19, Pharmaceutical industry, Vaccine

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLDSymposium in San Diego.

Key Points: 
  • AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLDSymposium in San Diego.
  • These interim data increase our confidence in the safety and efficacy of our gene therapy approach using the patients own hematopoietic stem cells and lay the groundwork for the AVROBIO-sponsored clinical trial for cystinosis planned to begin in 2023.
  • The collaborator-sponsored Phase 1/2 clinical trial is evaluating the safety and efficacy of AVR-RD-04 in adult patients who previously had been treated with cysteamine.
  • AVROBIOs pipeline is powered by our industry-leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide.

Cystic Fibrosis Drug Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
General Health, Pharmaceutical, Genetics, Health, Clinical trial, Discovery, CAP, Fibrosis, Infection, Route, Administration, Therapy, Patient, Route of administration, News, Cysteamine, Elections Reform Support Group, II, Pharmaceutical industry

The "Cystic Fibrosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cystic Fibrosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Cystic Fibrosis - Pipeline Insight, 2021 provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Cystic Fibrosis pipeline landscape.
  • This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.